The global peptide CDMO market, in its telling, has gone from a $1-1.5 billion category to $5-6 billion in just a few years and most of that explosion is downstream of GLP-1s success, which has made innovators want to develop the next generation of peptide drugs
Your first thought shouldn't be " buT stUDy OnLY hAs 5 PaTIenTs as A SAMplE", it should be "That's not supposed to happen, holy shit , this is potentially a huge deal", yet here we are , speaking about NVDAs finances and why theyre not Enron why T1D going from there to not there maybe deserves a bit of attention as the result is peer reviewed
Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are once-weekly weight loss injections in the UK, available privately and, in certain cases, through NHS frameworks
Extended Data Figure 4 Effects of binding pocket mutations on potency of NAMs
Gitanjali Srivastava, Vanderbilt Medical Center Table of Contents Part 1: Advantages of GLP-1RAs for Addiction Part 2: Research Evidence Part 3: Towards Broad Adoption Introduction Evidence that GLP-1 treatments like Ozempic and Mounjaro have strong anti-addictive effects across substances and behaviors has been mounting every month